The EndoPredict(R) test significantly outperforms the first-generation test
Myriad announced results of a large head-to-head study comparing efficacy of six tests used to predict recurrence of breast cancer. A key finding was EndoPredict®, a second-generation test, was superior to Oncotype Dx™, a first-generation test, in predicting long-term recurrence of breast cancer. December 09, 2016